{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T19:09:31Z","timestamp":1773515371050,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.semarthrit.2019.09.019","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T18:06:28Z","timestamp":1574705188000},"page":"S3-S7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"S","title":["Challenges in systemic sclerosis trial design"],"prefix":"10.1016","volume":"49","author":[{"given":"Christopher P.","family":"Denton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2019.09.019_bib0001","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/rheumatology\/keu288","article-title":"Twenty-two points to consider for clinical trials in systemic sclerosis, based on Eular standards","volume":"54","author":"Khanna","year":"2015","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.semarthrit.2019.09.019_bib0002","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/art.22721","article-title":"Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model","volume":"56","author":"Shand","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2019.09.019_bib0003","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/ard.2005.050187","article-title":"Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study","volume":"65","author":"Khanna","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.09.019_bib0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5301\/jsrd.5000231","article-title":"Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis","volume":"2","author":"Khanna","year":"2017","journal-title":"J Scleroderma Relat Disord"},{"key":"10.1016\/j.semarthrit.2019.09.019_bib0005","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13075-015-0669-3","article-title":"Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis","volume":"17","author":"Chakravarty","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.09.019_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13075-017-1252-x","article-title":"Multiplex serum protein analysis reveals potential mechanisms and markers of response to hyperimmune caprine serum in systemic sclerosis","volume":"19","author":"Quillinan","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.09.019_bib0007","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/annrheumdis-2013-203674","article-title":"Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial","volume":"73","author":"Quillinan","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10038","key":"10.1016\/j.semarthrit.2019.09.019_bib0008","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.semarthrit.2019.09.019_bib0009","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","article-title":"Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis","volume":"77","author":"Denton","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2019.09.019_bib0010","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/art.40547","article-title":"Lysophosphatidic acid receptor 1 antagonist SAR100842 for patients with diffuse cutaneous systemic sclerosis: a double-blind, randomized, eight-week placebo-controlled study followed by a sixteen-week open-label extension study","volume":"70","author":"Allanore","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"25","key":"10.1016\/j.semarthrit.2019.09.019_bib0011","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2019.09.019_bib0012","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.semarthrit.2019.09.019_bib0013","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2019.09.019_bib0014","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semarthrit.2019.09.019_bib0015","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-Term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2019.09.019_bib0016","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2019.09.019_bib0017","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American college of rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"24","key":"10.1016\/j.semarthrit.2019.09.019_bib0018","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.semarthrit.2019.09.019_bib0019","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl 10","key":"10.1016\/j.semarthrit.2019.09.019_bib0020","article-title":"Efficacy and safety of tocilizumab for the treatment of systemic sclerosis: results from a phase 3 randomized controlled trial [abstract]","volume":"70","author":"Khanna","year":"2018","journal-title":"Arthritis Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017219306547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017219306547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T09:14:49Z","timestamp":1668590089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017219306547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0049017219306547"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.09.019","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in systemic sclerosis trial design","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2019.09.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}